| Assessment Status | NCPE assessment ongoing |
| HTA ID | 22060 |
| Drug | Faricimab |
| Brand | Vabysmo ® |
| Indication | For the treatment of adult patients with neovascular (wet) age-related macular degeneration. |
| Assessment Process | |
| Rapid review commissioned | 29/08/2022 |
| Rapid review completed | 04/10/2022 |
| Rapid review outcome | A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of faricimab compared with the current standard of care.* |
| Full pharmacoeconomic assessment commissioned by HSE | 25/10/2022 |
| Pre-submission consultation with Applicant | 03/10/2023 |
| Full submission received from Applicant | 12/06/2024 |
| Preliminary review sent to Applicant | 19/03/2025 |
| NCPE assessment re-commenced | 16/04/2025 |
| Factual accuracy sent to Applicant | 27/05/2025 |
| NCPE assessment re-commenced | 05/06/2025 |
*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods Act) 2013.